Cybin (HELP) Other Non-Current Liabilities (2021 - 2024)
Cybin (HELP) reported Other Non-Current Liabilities of $19.8 million for Q4 2024, down 16.33% on a YoY basis from $23.6 million in Q1 2024, and down 2.35% quarter-over-quarter from $20.2 million in Q3 2024.
Cybin (HELP) Other Non-Current Liabilities (2021 - 2024) Analysis & Trends
Cybin has reported Other Non-Current Liabilities for 4 years, with the latest figure at $19.8 million in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Liabilities fell 16.33% year-over-year to $19.8 million; the trailing twelve-month figure through Dec 2024 stood at $19.8 million (down 16.33% YoY), and the FY2024 full-year result was $19.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2024 stood at $19.8 million, down from $20.2 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $23.6 million in Q4 2023, with the low at $8.0 million in Q4 2022.
- Historically, Other Non-Current Liabilities has averaged $13.3 million across 4 years, with a median of $9.3 million in 2021.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 194.72% — and 2024, when it dropped 16.33%.
- Cybin's Other Non-Current Liabilities stood at $9.2 million in 2021, then declined by 13.0% to $8.0 million in 2022, then surged by 194.72% to $23.6 million in 2023, then dropped by 16.33% to $19.8 million in 2024.
- The last three Other Non-Current Liabilities figures came in at $19.8 million (Q4 2024), $20.2 million (Q3 2024), and $18.7 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 19.75 Mn |
| Sep 30, 2024 | 20.23 Mn |
| Jun 30, 2024 | 18.75 Mn |
| Mar 31, 2024 | 19.03 Mn |
| Dec 31, 2023 | 23.61 Mn |
| Sep 30, 2023 | 10.68 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Dec 31, 2022 | 8.01 Mn |
| Sep 30, 2022 | 8.64 Mn |
| Dec 31, 2021 | 9.21 Mn |
| Sep 30, 2021 | 9.29 Mn |
| Jun 30, 2021 | 9.13 Mn |
| Mar 31, 2021 | 8.82 Mn |